Table of Contents
Trial overview
The available trial is an open-label, single-arm, non-controlled study of Treprostinil Sodium in children with pulmonary arterial hypertension (PAH).[1] It is authorised and includes 37 participants.[1]
The study title says it is designed to evaluate the safety and tolerability of treprostinil sodium in children below 18 years of age with PAH.[1] The brief summary also says the study is for paediatric patients with PAH who are either treatment naive or have previously been treated with commercially available parenteral treprostinil formulation.[1]
Who can participate
The trial is for paediatric patients, meaning children and teenagers below 18 years of age.[1] They must have pulmonary arterial hypertension, also called PAH.[1]
The study includes two main patient groups: people who are treatment naive, which means they have not been treated before, and people who have already received commercially available parenteral treprostinil.[1]
What the trial measures
The main outcome is the frequency and seriousness of adverse events and adverse drug reactions during the first 5 months of treatment, or 20 weeks plus or minus 1 week.[1] An adverse event is any health problem that happens during a study, and an adverse drug reaction is a harmful reaction thought to be related to the study drug.[1]
The study uses CTCAE version 5.0, which is a standard system for grading how serious these problems are.[1] This means the trial is mainly focused on safety and tolerability rather than direct comparison with another treatment.[1]
Study design and phase
This is a Phase 3 interventional trial, meaning the researchers are testing a treatment in people and studying its effects in a later-stage trial.[1] Because it is single-arm and non-controlled, all enrolled participants receive the study treatment and there is no separate comparison group.[1]
The interventions listed in the trial include TREPaed_10, TREPaed_5, TREPaed_0.5, TREPaed_2.5, and TREPaed_1, each described as 155 ng and for subcutaneous and intravenous use.[1]
Key patient terms
Subcutaneous means under the skin, and intravenous means into a vein.[1] Parenteral means given by a route other than the digestive system, such as injection or infusion.[1]
Safety in a trial means checking whether the treatment causes medical problems, while tolerability means how well patients can take the treatment without major difficulty.[1] The trial data show that these are the main questions being studied for Treprostinil Sodium in children with PAH.[1]
